Tsubouchi Saki, Tsukamoto Yo, Ishikawa Ai, Shigemori Rintaro, Kato Daiki, Shibazaki Takamasa, Mori Shohei, Nakada Takeo, Odaka Makoto, Ohtsuka Takashi
Department of Surgery, The Jikei University School of Medicine, Nishishinbashi 3-19-18, Minatoku, Tokyo, 105-8471, Japan.
Department of Surgery, The Jikei University Kashiwa Hospital, 163-1 Kashiwashita Kashiwashi, Chiba, 277-8567, Japan.
Surg Case Rep. 2024 May 27;10(1):130. doi: 10.1186/s40792-024-01927-5.
Distant metastases of ovarian cancer are rarely detected alone. The effectiveness of surgical intervention for pulmonary metastases from ovarian cancer remains uncertain. This study aimed to investigate the clinicopathologic characteristics and outcomes of patients undergoing resection for pulmonary metastasis from ovarian cancer.
The clinicopathologic characteristics and outcomes of radical surgery for pulmonary metastasis from ovarian cancer were investigated. Out of 537 patients who underwent pulmonary metastasis resection at two affiliated hospitals between 2010 and 2021, four (0.74%) patients who underwent radical surgery for pulmonary metastasis from ovarian cancer were included. The patients were aged 67, 47, 21, and 59 years; the intervals from primary surgery to detection of pulmonary metastasis from ovarian cancer were 94, 21, 36, and 50 months; and the overall survival times after pulmonary metastasectomy were 53, 50, 94, and 34 months, respectively. Three of the four patients experienced recurrence after pulmonary metastasectomy. Further, preoperative carbohydrate antigen (CA) 125 levels were normal in two surviving patients and elevated in the two deceased patients.
In this study, three of the four patients experienced recurrence after pulmonary metastasectomy, but all patients survived for > 30 months after surgery. Patients with ovarian cancer and elevated CA125 levels may not be optimal candidates for pulmonary metastasectomy. To establish appropriate criteria for pulmonary metastasectomy in patients with ovarian cancer, further research on a larger patient cohort is warranted.
卵巢癌的远处转移很少单独被发现。卵巢癌肺转移手术干预的有效性仍不确定。本研究旨在调查接受卵巢癌肺转移切除术患者的临床病理特征及预后。
对卵巢癌肺转移根治性手术的临床病理特征及预后进行了调查。在2010年至2021年间于两家附属医院接受肺转移切除术的537例患者中,纳入了4例(0.74%)接受卵巢癌肺转移根治性手术的患者。患者年龄分别为67岁、47岁、21岁和59岁;从初次手术到发现卵巢癌肺转移的间隔时间分别为94个月、21个月、36个月和50个月;肺转移切除术后的总生存时间分别为53个月、50个月、94个月和34个月。4例患者中有3例在肺转移切除术后复发。此外,两名存活患者术前糖类抗原(CA)125水平正常,两名死亡患者的该指标升高。
在本研究中,4例患者中有3例在肺转移切除术后复发,但所有患者术后均存活超过30个月。CA125水平升高的卵巢癌患者可能不是肺转移切除术的最佳候选者。为了建立卵巢癌患者肺转移切除术的合适标准,有必要对更大的患者队列进行进一步研究。